Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Files for $750M Notes Offering

NEW YORK (GenomeWeb News) – Agilent Technologies has filed a prospectus with the US Securities and Exchange Commission to offer $750 million in senior notes.

The firm said that of these notes, $500 million will mature in September 2015 and will bear an annual interest rate of 5.5 percent, while $250 million will mature in September 2012 with an annual interest rate of 4.45 percent.

Agilent said that it intends to use the proceeds from the offering for general corporate purposes, which may include its acquisition of Varian, other acquisitions, capital expenditures, or repurchasing its common stock.

Agilent announced at the end of July that it would acquire Varian for around $1.5 billion. The deal is expected to expand Agilent's presence in the life sciences research and applied markets, such as the environment and energy.

The company expects to close the offering on Sept. 14, 2009.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.